Media coverage about DURECT Corporation (NASDAQ:DRRX) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DURECT Corporation earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 46.8128374564892 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
- The Stock Market Cycle And Implications For Medical Stock Investing (seekingalpha.com)
- Stock Watch Evaluation – DURECT Corporation, (NASDAQ: DRRX) – Stock Watch (stocksnewstimes.com)
- Analyst Says Biotech Share Price Could Potentially ‘Double’ (streetwisereports.com)
- Financial Survey: MacroGenics (MGNX) and DURECT Corporation (DRRX) (americanbankingnews.com)
- DURECT Corporation (DRRX) Sees Large Increase in Short Interest (americanbankingnews.com)
A number of equities analysts have commented on the stock. Stifel Nicolaus downgraded shares of DURECT Corporation from a “buy” rating to a “hold” rating in a report on Friday, October 20th. ValuEngine upgraded shares of DURECT Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Laidlaw reduced their target price on shares of DURECT Corporation from $3.00 to $2.00 and set a “buy” rating for the company in a report on Friday, October 20th. Finally, HC Wainwright downgraded shares of DURECT Corporation from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a report on Friday, October 20th.
DURECT Corporation (NASDAQ:DRRX) last announced its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.09. The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $5.09 million. DURECT Corporation had a negative net margin of 62.57% and a negative return on equity of 419.65%. sell-side analysts anticipate that DURECT Corporation will post -0.14 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “DURECT Corporation (DRRX) Receives Daily News Impact Rating of 0.13” was originally published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2017/11/20/durect-corporation-drrx-receives-daily-news-impact-rating-of-0-13.html.
DURECT Corporation Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.